Monthly Archives: November 2014

Building a performance based corporate culture is a key aspect of the biotech innovation business.  It can be easy to overlook this facet of company building as one focuses on determining the robustness of the new technology, refining your business

The cost of making a new drug has grown to nearly $2.6B, according to the latest and greatest from Tufts Center for the Study of Drug Development (here).  That’s a big and almost unfathomable number.  Critics immediately pounced on it,

As one of big drivers behind the recent IPO window, cross-over investing into private biotech companies by both mutual fund and hedge fund investors has become increasingly commonplace over the past couple years.  As described at the BIO Investor meeting